A New Treatment for Type 2 Diabetes; The Problem of Chemotherapy for Oldest-Old Patients; Clarithromycin and Cardiovascular Events
Fed Pract. 2013 July;30(7):40-41
Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, approved by the FDA, works differently from other diabetes drugs: It blocks the kidneys from reabsorbing glucose via SGLTs, increasing glucose excretion.
